Abstract:Background Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter 2) inhibitors exert hypotensive effect and cardiorenal protective benefits in patients with hypertension with and without diabetes. However, the underlying mechanism remains elusive. Methods and Results Dahl salt‐sensitive rats and salt‐insensitive controls were fed with 8% high‐salt diet and some of them were treated with canagliflozin. The blood pressure, urinary sodium excretion, and vascular function were detected. Transient receptor potential channel 3 (TRPC3) knockout mice were used to explain the mechanism. Canagliflozin treatment significantly reduced high‐salt‐induced hypertension and this effect was not totally dependent on urinary sodium excretion in salt‐sensitive hypertensive rats. Assay of vascular function and proteomics showed that canagliflozin significantly inhibited vascular cytoplasmic calcium increase and vasoconstriction in response to high‐salt diet. High salt intake increased vascular expression of TRPC3 in salt‐sensitive rats, which could be alleviated by canagliflozin treatment. Overexpression of TRPC3 mimicked salt‐induced vascular cytosolic calcium increase in vitro and knockout of TRPC3 erased the antihypertensive effect of canagliflozin. Mechanistically, high‐salt‐induced activation of NCX1 (sodium‐calcium exchanger 1) reverse mode increased cytoplasmic calcium level and vasoconstriction, which required TRPC3, and this process could be blocked by canagliflozin. Conclusions We define a previously unrecognized role of TRPC3/NCX1 mediated vascular calcium dysfunction in the development of high‐salt‐induced hypertension, which can be improved by canagliflozin treatment. This pathway is potentially a novel therapeutic target to antagonize salt‐sensitive hypertension. Nonstandard Abbreviations and Acronyms [Ca 2+ ]cyt cytosolic free calcium concentration NCX1 sodium‐calcium exchanger 1 ND normal diet SGLT2i sodium‐glucose exchanger 2 inhibitor SS Dahl salt‐sensitive rats SS‐19BN Dahl salt‐insensitive rats TRPC3 transient receptor potential channels 3 Clinical Perspective What Is New? The SGLT2 (sodium‐glucose cotransporter 2) inhibitor canagliflozin antagonizes salt‐induced hypertension in salt‐sensitive rats by directly alleviating vasoconstriction. Salt‐induced vascular transient receptor potential channel 3 upregulation results in an augmented vasoconstriction in salt‐sensitive hypertensive rats through facilitating NCX1 (sodium‐calcium exchanger 1)‐mediated vascular calcium uptake, which could be alleviated by canagliflozin. What Are the Clinical Implications? Antagonizing the interaction between transient receptor potential channel 3 and NCX1 by the SGLT2 inhibitor canagliflozin would represent a novel target to antagonize salt‐sensitive hypertension. Canagliflozin exerts its antihypertensive effect beyond its canonical effect on renal natriuresis. Cardiovascular disease has always been the biggest threat to human health. 1 Chronic vascular diseases such as hypertension and atherosclerosis are the main pathogenic factors or early pathological processes of high‐mortality diseases such as coronary heart disease, myocardial infarction, and heart failure. High salt intake not only acts as an independent risk factor for hypertension but also causes cardiovascular and renal damage. 2 , 3 High salt intake raises blood pressure (BP) through activation of the sympathetic nerve system and renin‐angiotensin system and leads to renal sodium retention. 4 Modest reduction in dietary salt intake substantially reduces cardiovascular events in the general population, but daily salt intake has remained unchanged in the past 2 decades. 5 , 6 Thus, to identify an alternative therapy for reducing t -Abstract Truncated-

Evaluating the potential impact of sodium–glucose cotransporter‐2 inhibitor "canagliflozin" on the hepatic damage triggered by hypertension in rats

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats

Canagliflozin ameliorates high glucose-induced apoptosis in NRK-52E cells via inhibiting oxidative stress and activating AMPK/mTOR-mediated autophagy

Canagliflozin Ameliorates the Development of NAFLD by Preventing NLRP3-mediated Pyroptosis Through FGF21-ERK1/2 Pathway

Canagliflozin Provides Cardioprotection and Renoprotection Against Isoprenaline‐induced Oxidative Stress by Stimulating AMPK‐Akt‐eNOS‐NO Signaling Axis

Canagliflozin Attenuates Hepatic Steatosis and Atherosclerosis Progression in Western Diet-Fed ApoE-Knockout Mice

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.

Empagliflozin Enhances Autophagy, Mitochondrial Biogenesis, and Antioxidant Defense and Ameliorates Renal Ischemia/Reperfusion in Nondiabetic Rats

Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling.

Sodium‐Glucose Cotransporter‐2 Inhibitor Suppresses Endoplasmic Reticulum Stress and Oxidative Stress in Diabetic Nephropathy Through Nrf2 Signaling: A Clinical and Experimental Study

Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes

Effects of Canagliflozin on Weight Loss in High-Fat Diet-Induced Obese Mice.

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes and Protects Diabetic Mouse Hearts by Inhibiting the Mtor/hif-1Α Pathway

AMPK-mediated autophagy is involved in the protective effect of canagliflozin in the vitamin D3 plus nicotine calcification model in rats

Abstract 14007: Sodium-Dependent Glucose Transporters 2 Inhibition Ameliorates Obesity-Induced Metabolic Changes and Cardiomyopathy

Canagliflozin Attenuates Lipotoxicity in Cardiomyocytes and Protects Diabetic Mouse Hearts by Targeting the mTOR/HIF-1α Pathway

Neuroprotective effect of canagliflozin against cisplatin-induced cerebral cortex injury is mediated by regulation of HO-1/PPAR-γ, SIRT1/FOXO-3, JNK/AP-1, TLR4/iNOS, and Ang II/Ang 1–7 signals

Metabolomic Analysis of the Effect of Canagliflozin on HFpEF Rats and Its Underlying Mechanism

Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH